Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial

• Hoofdauteurs: Juliana Park (Auteur), Sophia Archuleta (Auteur), May-Lin Helen Oh (Auteur), Lynette Pei-Chi Shek (Auteur), Hao Wang (Auteur), Matthew Bonaparte (Auteur), Carina Frago (Auteur), Alain Bouckenooghe (Auteur), Frederique Jantet-Blaudez (Auteur), Sarah Begue (Auteur), Sophie Gimenez-Fourage (Auteur), Anke Pagnon (Auteur)
• Formaat: Boek
• Gepubliceerd in: Taylor & Francis Group, 2021-07-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NC...